Flibanserin’s approval wasn’t based on a single study; the FDA considered several clinical trials. These trials measured improvements in the Female Sexual Function Index (FSFI) score, a common metric for assessing sexual function. Women taking flibanserin showed statistically significant increases in their FSFI scores compared to placebo groups. The improvement, however, was modest.
Specific Trial Data
One pivotal study reported an average increase of 2.2 points on the FSFI for women taking flibanserin versus 1.1 points for the placebo group. This difference, while statistically significant, translates to a relatively small change in the overall sexual experience. Other studies revealed similar, though not identical, results. It’s important to note that not all women taking flibanserin experienced improvement, and the magnitude of the improvement varied widely.
Considerations for Patients
Before starting flibanserin, patients should discuss potential side effects with their doctors, including dizziness, nausea, and sleepiness. The drug’s efficacy depends on individual responses and factors like overall health. While studies show a positive effect for some women, it’s not a guaranteed solution for all experiencing hypoactive sexual desire disorder (HSDD). The available data suggests a moderate level of success for some, but not a universal remedy.
